TLR9: an important molecule in the fight against hepatitis B virus

Author
Shahrakyvahed, Aziz, Sanchooli, Javad, Sanadgol, Nima, Arababadi, Mohammad Kazemi, Kennedy, Derek

Published
2014

Journal Title
Postgraduate Medical Journal

DOI
10.1136/postgradmedj-2013-132309

Rights statement
© The Author(s) 2014. The attached file is reproduced here in accordance with the copyright policy of the publisher. For information about this journal please refer to the journal's website or contact the authors.

Downloaded from
http://hdl.handle.net/10072/63895

Griffith Research Online
https://research-repository.griffith.edu.au
TLR9: an important molecule in the fight against hepatitis B virus

Aziz Shahrakyvahed,1 Javad Sanchooli,2 Nima Sanadgol,3,4 Mohammad Kazemi Arababadi,5 Derek Kennedy6

ABSTRACT

Hepatitis B virus (HBV) is the most prevalent infectious agent that can induce severe liver disease. Patients infected with long-term HBV, including chronic, asymptomatic and occult forms, cannot clear HBV from infected hepatocytes completely. It is not clear why some people can clear the infection while others cannot. Furthermore, the main mechanisms responsible for progression of the infections are not fully understood. It has been hypothesised that differences in genetic and immunological parameters between patients and subjects who successfully clear HBV infections are responsible for inducing the long-term forms of the infection. Previous investigations showed that Toll-like receptors (TLRs) play important roles in immune responses, especially innate immunity, against viral infections, including hepatitis B. TLR9 detects intracellular viral dsDNA, which results in the activation of an immune response against HBV. However, defects in this system may result in an attenuated response ultimately leading to long-term HBV infections. Targeting the defects in TLR9 or reactivating the downstream pathways that are normally switched on by TLR9 in response to HBV infection is a new approach to the treatment of long-term HBV infection. However, the pathways and defects seen in patients with long-term HBV need to be thoroughly explored before therapeutics can be applied in the clinical setting. Furthermore, the apparently multigenic nature of long-term HBV infection suggests that treatment of patients may need to be personalised.

INTRODUCTION

Hepatitis B virus (HBV) is the most prevalent infectious agent of the liver and induces hepatitis B in humans.1–3 Patients infected with long-term HBV, such as those with chronic, asymptomatic and occult HBV infection, cannot clear HBV from either hepatocytes or serum samples.4,5 Previous studies have proposed that prolonged-term HBV infections might be the main causes of cirrhosis of the liver and hepatocellular carcinoma (HCC).6–7 However, the main mechanisms responsible for development of the prolonged forms of HBV infections are yet to be identified and it has been suggested that genetic and immunological differences between patients and subjects who successfully clear HBV infections (the clearance group) may be the main reasons for persistent forms of the infection.1,5,8 Alternatively, the infecting virus might carry ‘escape’ mutations helping it to avoid detection by the host. Escape mutations with HBV are discussed elsewhere.9 Toll-like receptors (TLRs) are the main intracellular/extracellular immune cell receptors that play key roles in pathogen-associated molecular pattern or ‘PAMP’ (table 1) recognition. TLRs convert pathogen recognition by the activation of immune responses against viruses, including hepatitis B.10 TLR/PAMP interactions induce several immune cell functions, ranging from phagocytosis,11 migration,12 nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation13 to inflammatory cytokine expression.14 Accordingly, TLR9 activation leads to the expression of inflammatory cytokines, major histocompatibility complexes and homing molecules, via the detection of intracellular viral dsDNA in a MYD88-dependent manner.15 Therefore, impaired expression of TLR9 may result in attenuated immune responses against HBV infection. Based on the fact that the immune system of patients infected with prolonged-term HBV cannot completely clear HBV from hepatocytes,16–18 it appears that these patients have defects in some parameters of their immune systems. TLR9 plays an important role in the detection and induction of immune responses against viral infection, and alterations in TLR9 expression may result in survival of HBV in the infected liver of patients with long-term HBV. Therefore the role of TLR9 in HBV recognition and subsequent host immune responses needs to be clarified because a complete understanding of the response to this infection may lead to therapeutic agents directed towards the reactivation of an immune response in those patients defective in this pathway. Figures 1 and 2 present the TLR9 signalling pathways which result in activation of immune responses. The figures also highlight the mechanisms used by HBV to suppress TLR9 signalling and thereby escape the normal immune response. These pathways provide insight into how treatments might target the reactivation of the immune system so that a patient could clear the infection.

HISTORY, GENOMIC LOCATION AND STRUCTURE OF TLR9

TLR9 was first cloned and determined as a receptor for unmethylated CpG-DNA, bacterial, viral and parasite DNA in 2000.19 The gene encoding this receptor is located on 3p21.3 and the protein encoded by the gene is highly conserved and plays a key role in pathogen recognition and activation of immune responses. This molecule is a type I transmembrane protein, with its N-terminal, which consists of leucine-rich repeats (LRRs), on the outside of the membrane. This is followed by a hydrophobic transmembrane domain and a cytoplasmic Toll/interleukin 1 receptor (TIR) domain.


CrossMark
Once activated, the TLR9/ligand complex triggers organelles, including the endosome and the endoplasmic reticulum (ER).20 Once activated, the TLR9/ligand complex triggers the activation of various intracellular signalling molecules and transcription factors to elicit an immune response to the recognised pathogen.

**TLR9 LIGANDS**

Antigens are ligands that are carried or presented by an invading pathogen and are specifically recognised by receptors on host immune cells. Once an antigen or ligand has bonded to a receptor and activated a downstream pathway, a normal immune response to the pathogen is expected. However, if the pathway is disrupted, attenuated or defective, the pathogen can proceed unhindered. Candidate treatments for long-term HBV infection need to consider which pathways are disrupted during HBV infection so that they can be reactivated. Previous studies showed that intracellular signalling of TLR9, like other TLRs, is MYD88 dependent.29 After TLR9/CpG-ODNs interaction, the TIR domains of TLR9 and MYD88 interact with each other.30 Activated MYD88 interacts with IRAK1 and IRAK4 via the death domain, which leads to recruitment of TRAF3 and TRAF6.31 This event activates TAK1, mitogen-activated protein kinase (MAPK), AP-1 and NF-κB.32 33 NF-κB is a transcription factor for several genes, including cytokines, chemokines, addressing and homing molecules as well as costimulatory molecules such as CD80 and CD86 and other molecules that will not be discussed here but are reviewed elsewhere.34 In addition, IRAK1 and TRAF3 directly and indirectly, respectively, activate IRF7, which plays a key role in the transcriptional activation of type I interferon.32 Expression of type I interferons are the first immune responses against viral infections including HBV.16 The typical signalling pathway is shown in the figure 1.

**THE INTRACELLULAR SIGNALLING PATHWAY OF TLR9**

Once a ligand has bound to a receptor and activated a downstream pathway, a normal immune response to the pathogen is expected. However, if the pathway is disrupted, attenuated or defective, the pathogen can proceed unhindered. Candidate treatments for long-term HBV infection need to consider which pathways are disrupted during HBV infection so that they can be reactivated. Previous studies showed that intracellular signalling of TLR9, like other TLRs, is MYD88 dependent.29 After TLR9/CpG-ODNs interaction, the TIR domains of TLR9 and MYD88 interact with each other.30 Activated MYD88 interacts with IRAK1 and IRAK4 via the death domain, which leads to recruitment of TRAF3 and TRAF6.31 This event activates TAK1, mitogen-activated protein kinase (MAPK), AP-1 and NF-κB.32 33 NF-κB is a transcription factor for several genes, including cytokines, chemokines, addressing and homing molecules as well as costimulatory molecules such as CD80 and CD86 and other molecules that will not be discussed here but are reviewed elsewhere.34 In addition, IRAK1 and TRAF3 directly and indirectly, respectively, activate IRF7, which plays a key role in the transcriptional activation of type I interferon.32 Expression of type I interferons are the first immune responses against viral infections including HBV.16 The typical signalling pathway is shown in the figure 1.

**Table 1 Abbreviations used within the article and descriptions of their terminology**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full terminology</th>
<th>Brief description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP-1</td>
<td>Activator protein 1</td>
<td>A transcription factor which is activated after TLRs/ligand interaction</td>
</tr>
<tr>
<td>BCL-2</td>
<td>B-cell lymphoma 2</td>
<td>An anti-apoptotic molecule</td>
</tr>
<tr>
<td>CCLs</td>
<td>CC ligands</td>
<td>A cluster of chemokines</td>
</tr>
<tr>
<td>CXCLs</td>
<td>CXC ligands</td>
<td>A cluster of chemokines</td>
</tr>
<tr>
<td>CTL</td>
<td>Cytotoxic T lymphocyte</td>
<td>T lymphocyte which kills infected and cancer cells</td>
</tr>
<tr>
<td>DNMT-1</td>
<td>DNA methyltransferase 1</td>
<td>A protein in the TLR signalling pathway</td>
</tr>
<tr>
<td>HBsAg</td>
<td>Hepatitis B surface antigen</td>
<td>Surface protein of HBV</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B virus</td>
<td>A DNA virus which infects the liver</td>
</tr>
<tr>
<td>HCC</td>
<td>Hepatocellular carcinoma</td>
<td>Cancer of liver</td>
</tr>
<tr>
<td>Interleukins</td>
<td>ILs</td>
<td>A subclass of cytokines which are used by a host to enhance immune responses</td>
</tr>
<tr>
<td>IRAKs</td>
<td>Interleukin-1 receptor associated kinases</td>
<td>Signalling molecules in the TLRs activation pathway</td>
</tr>
<tr>
<td>IRF7</td>
<td>Interferon regulatory factor 7</td>
<td>A transcription factor which is activated after TLRs/ligand interaction</td>
</tr>
<tr>
<td>JAK1</td>
<td>Janus kinase 1</td>
<td>Cytokine receptor signalling molecules</td>
</tr>
<tr>
<td>LRRs</td>
<td>Leucine-repeat proteins</td>
<td>Extracellular domain of TLRs</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
<td>An intracellular signalling pathway which results in activation of AP-1</td>
</tr>
<tr>
<td>MYD88</td>
<td>Myeloid differentiation primary response</td>
<td>An adaptor molecule in TLRs signalling</td>
</tr>
<tr>
<td>NADPH</td>
<td>Nicotinamide adenine dinucleotide phosphate</td>
<td>A coenzyme which is used in anabolic reactions</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear factor kappa-light-chain-enhancer of activated B cells</td>
<td>A transcription factors which is activated after TLRs/ligand interaction</td>
</tr>
<tr>
<td>PBMC</td>
<td>Peripheral blood mononuclear cell</td>
<td>Immune cells within peripheral blood, often considered as the white blood cells</td>
</tr>
<tr>
<td>STAT3</td>
<td>Signal transducer and activator of transcription 3</td>
<td>Cytokine receptor signalling molecules</td>
</tr>
<tr>
<td>TAK1</td>
<td>Transforming growth factor b-activated kinase 1</td>
<td>A protein in the TLR signalling pathway</td>
</tr>
<tr>
<td>TIR</td>
<td>Toll/interleukin 1 receptor</td>
<td>Intracellular domain of TLRs</td>
</tr>
<tr>
<td>TRAF6</td>
<td>TNF receptor associated factor</td>
<td>A protein in the TLR signalling pathway</td>
</tr>
</tbody>
</table>

TLR, Toll-like receptor; TNF, tumour necrosis factor.
HBV-DNA can be recognised by TLR9

TLR9/HBV-DNA interactions are normally the main mechanism leading to activation of immune cells. For instance, Cui and Diao, reported that introducing HBV-DNA to pDCs led to activation of the NF-κB, MAPK and IRF7 molecules, which resulted in secretion of type I interferons and inflammatory cytokines and maturation of DCs. Additionally, studies on primary primate hepatocytes showed that TLR9/ligand interactions led to the production of inflammatory cytokines. Wu et al. also demonstrated that TLR9 activation induces production of antiviral cytokines in myeloid DCs derived from the liver of C57/BL6 wild-type mice. These findings highlight how TLR9 activation, by the recognition of foreign DNA, is one of the main mechanisms used by a host to recognise HBV and activate an immune response.

Expression of TLR9 and its signalling molecules is disrupted in patients infected with chronic HBV (CHB)

Patients infected with long-term HBV cannot eradicate the virus from hepatocytes completely and this may be caused by a defect in TLR9 expression or signalling. Accordingly, previous studies showed that the expression of TLR9, MYD88, IRAK1, IRAK4, TRAF3, IRF7, NF-κB and TRAF6 in the circulating white blood cells of peripheral blood mononuclear cells (PBMCs) taken from patients infected with CHB were significantly decreased in comparison with healthy controls. Martinet et al. found that pDCs from patients infected with CHB displayed defective responses to stimulation with TLR9 ligands and were unable to induce cytolytic activity of NK cells. This result was supported in a study by Xu and colleagues, which introduced TLR9 ligands to pDCs and found impaired type I interferon responses. Ratnam and colleagues reported that the stimulated NK cells of patients infected with CHB had an impaired interferon γ response to TLR9 ligands in comparison with controls. Another study showed that mRNA levels of TLR9 were negatively correlated with serum levels of liver enzymes, while, positively associated with HBV viral load in patients with CHB. Zhou et al. also reported that expression levels of TLR9 were significantly decreased in patients with CHB. In parallel with these results, Xie and colleagues showed that expression levels of TLR9 mRNA and protein levels were decreased in pDCs of patients with CHB in comparison with healthy controls. The current literature suggests that TLR9 expression and function are compromised in the immune cells taken from patients with prolonged forms of hepatitis B infection and this may be important in understanding how infection persists in those patients.

HBV interferes with expression and function of TLR9 and its signalling molecules

Several factors influence TLR9 expression in patients with prolonged forms of hepatitis B, and this attenuates the host’s ability to raise an immune response to the infection. Shi et al. showed that HBsAg inhibited TLR9 expression on pDCs either by direct
effects on pDCs or indirectly through the induction of monocytes to release interleukin 10 (IL-10) (figure 2). IL-10 leads to downregulation of several inflammatory molecules via the JAK1/STAT3 signalling pathway, hence, this mechanism may be responsible for downregulation of TLR9 by the indirect effects of HBsAg (figure 2). Xu et al also reported that HBsAg can suppress TLR9 transcription in pDCs. However, a complete picture of the mechanisms explaining the direct effect of HBsAg on the decreased expression of TLR9 in pDCs has yet to be clarified. Vincent and colleagues also showed that HBV led to downregulation of TLR9 at the transcriptional level in pDCs and B cells in which TLR9 mRNA and protein levels were decreased. The researchers showed that HBV can affect TLR9 activity by blocking the MYD88–IRAK4 axis. Interestingly, another study showed that HBeAg-positive patients displayed impaired interferon α production in response to CpG-ODNs by pDCs compared with HBeAg-negative patients and healthy controls. Thus, it seems that HBeAg can also inhibit TLR9 activation via unknown mechanisms. Hirsch et al also demonstrated that HBV can lead to decreased expression of TLR9 and interferon α in pDCs via interactions with the regulatory receptors of pDCs. Downregulation of TLR9 expression was also reported in patients with CHB with high HBV-DNA copy numbers in comparison with patients with low HBV-DNA copy numbers. In addition, the existence of neutralising CpG motif sequences within the DNA genome of HBV genotypes A to H may also be considered as plausible mechanisms for the inhibitory effects on TLR9-immune activation. The data presented in these studies overwhelmingly suggest that HBV-DNA may directly decrease expression of TLR9 in immune cells. Regardless of the mechanism, the data suggest that infection by HBV can reduce the efficacy of the TLR9 responses and this may tip the balance in favour of the virus in those patients who cannot clear the infection through alternative immune responses.

**Host genetic and epigenetic variations are responsible for downregulation of TLR9 and its signalling molecules**

The genotype of the host may also present a potential candidate for decreased expression of TLR9 in the immune cells of patients with prolonged forms of hepatitis B. Although it may not be possible to identify the genetic changes, it may be possible to assess their effects by looking at the diseases associated with long-term HBV infection. For instance, Jia et al reported that the polymorphisms within the TLR9 gene were significantly associated with HBV-related liver cirrhosis. Wu et al also found that the polymorphisms within the promoter region of TLR9 were significantly associated with earlier spontaneous HBeAg sero conversion. In addition, an association of TLR9 with HBV-related hepatocellular carcinoma has been reported by Liu et al. They showed that mRNA of DNMT-1 and BCL-2 were raised when hepatocytes were stimulated with HBV-DNA. It also appears that TLR9 can play a crucial role in the immunopathogenesis of hepatitis B. Previous studies demonstrated that micro-RNAs play critical roles in regulation of gene expression, and hence, HBV or host encoded micro-RNAs may contribute to the downregulation of TLR9.

**Figure 2** The mechanisms used by HBV to suppress TLR9 signaling pathway.
micro-RNAs may affect TLR9 expression and its signalling molecules in these patients. Furthermore, the author of this review article also hypothesises that, in addition to the factors and mechanisms reported above, epigenetics may regulates expression of genes required for complete clearance of HBV and altered expression may contribute to the downregulation of TLR9 in patients infected with prolonged HBV and associated diseases.

CONCLUSIONS
The accumulated data highlight the key role of TLR9 in the induction of humoral and cellular immune responses against hepatitis B. Accordingly, it is not surprising that patients infected with prolonged HBV are unable to express suitable levels of TLR9 and its signalling molecules to induce expression of essential inflammatory factors, including proinflammatory cytokines, chemokines and costimulatory molecules that are required for the eradication of the HBV infection. Future treatments could focus on strategies which can upregulate the expression of TLR9 and its signalling molecules as a way of reactivating the immune responses and facilitating the eradication of HBV from patients infected with prolonged HBV. Additionally, the results suggest that TLR9 ligands can be considered as a powerful target for adjuvants to use in HBV vaccination, especially in patients who fail to respond to conventional vaccination. Future studies can be directed to discovering new ligands or to enhance current ligands for TLR9 to improve immune responses against HBV in patients with prolonged HBV. Alternatively, adjuvants designed to stimulate TLR9 responses could be used to improve humoral immune responses, especially in non-responding vaccinated subjects. Overall, several approaches need to be taken. Patients who do not respond to current vaccinations need to be identified and in these cases vaccinations that enhance TLR9 signals can be considered. In patients with long-term HBV the immune system needs to be activated so that the patient can clear the infection. Future treatments may focus on activating TLR9 and its downstream targets to kick-start the immune system. The best way to fight long-term HBV infection would be to use the patient’s own immune system and this, in turn, would limit the secondary diseases, such as cirrhosis of the liver and hepatocellular carcinoma, typically seen in these patients.

Current research questions

- Can the immune system of patients with long-term hepatitis B virus (HBV) be reactivated to recognise the pathogen?
- Can we remodelate the cytokine responses of patients with long-term HBV so that they can successfully clear the virus?
- Are there mechanisms that we can use, outside the host immune system, which can eradicate the pathogen from patients with long-term HBV?
- Can TLR9 be used as a target in treatments for long-term HBV infection?

Key references


REFERENCES


37 Cui GY, Diao HY. Recognition of HBV antigens and HBV DNA by dendritic cells. Hepatobiliary Pancreat Dis Int 2010;9:584–92.


TLR9: an important molecule in the fight against hepatitis B virus

Aziz Shahrakyvahed, Javad Sanchooli, Nima Sanadgol, et al.

doi: 10.1136/postgradmedj-2013-132309